CompletedPHASE2, PHASE3NCT00125203

Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The University of Texas Health Science Center at San Antonio
Principal Investigator
Carlayne E Jackson, MD
The University of Texas Health Science Center at San Antonio
Intervention
Botulinum toxin type B (Myobloc)(drug)
Enrollment
20 enrolled
Eligibility
21-85 years · All sexes
Timeline
20032007

Study locations (2)

Collaborators

ALS Association · University of Kansas · Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00125203 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials